Transplant complications and outcomes
| . | n (%) . |
|---|---|
| Status at last follow-up | |
| Alive | 620 (87) |
| Dead | 92 (13) |
| Cause of death (n = 92) | |
| Infections | 39 (42) |
| GVHD | 30 (33) |
| Toxicity/organ damage | 10 (11) |
| PTLD | 2 (2) |
| Other | 8 (9) |
| Missing data | 3 (3) |
| Donor engraftment | |
| Engraftment | 610 (88) |
| Primary GF | 13 (1.8) |
| Secondary GF | 71 (10.0) |
| Missing data | 18 (2.5) |
| Neutrophil recovery | |
| Median days after HSCT (range) | 18 (3.00, 133) |
| Missing data | 46 (6.5) |
| Platelet recovery | |
| Median days after HSCT (range) | 19 (3.00, 131) |
| Missing data | 202 (28.4) |
| aGVHD | |
| No aGVHD/grade I | 541 (76.0) |
| Grade II | 81 (11.4) |
| Grade III or IV | 64 (9.0) |
| Missing data | 26 (3.7) |
| cGVHD | |
| No cGVHD | 513 (72.1) |
| Limited | 53 (7.4) |
| Extensive | 33 (4.6) |
| Missing data | 113 (15.8) |
| . | n (%) . |
|---|---|
| Status at last follow-up | |
| Alive | 620 (87) |
| Dead | 92 (13) |
| Cause of death (n = 92) | |
| Infections | 39 (42) |
| GVHD | 30 (33) |
| Toxicity/organ damage | 10 (11) |
| PTLD | 2 (2) |
| Other | 8 (9) |
| Missing data | 3 (3) |
| Donor engraftment | |
| Engraftment | 610 (88) |
| Primary GF | 13 (1.8) |
| Secondary GF | 71 (10.0) |
| Missing data | 18 (2.5) |
| Neutrophil recovery | |
| Median days after HSCT (range) | 18 (3.00, 133) |
| Missing data | 46 (6.5) |
| Platelet recovery | |
| Median days after HSCT (range) | 19 (3.00, 131) |
| Missing data | 202 (28.4) |
| aGVHD | |
| No aGVHD/grade I | 541 (76.0) |
| Grade II | 81 (11.4) |
| Grade III or IV | 64 (9.0) |
| Missing data | 26 (3.7) |
| cGVHD | |
| No cGVHD | 513 (72.1) |
| Limited | 53 (7.4) |
| Extensive | 33 (4.6) |
| Missing data | 113 (15.8) |
Data are the number of patients (percentage of the total group), unless otherwise stated.
PTLD, posttransplant lymphoproliferative disorder.